We built the first link between GABRP and gemcitabine in pancreatic cancer, and we report, for the first time, that GABRP might be downstream of the CD44 effector gene in gemcitabine-resistant pancreatic cancer cells. This evidence concerns the gene CD44 and familial pancreatic carcinoma.